Skip to Content
Merck
CN

SML3880

Sigma-Aldrich

CST626

≥98% (HPLC)

Synonym(s):

(2S,4S)-1-((S)-2-Cyclohexyl-2-((S)-2-(methylamino)-propanamido)acetyl)-4-(3-((5-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)oxy)phenoxy)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)pyrrolidine-2-carboxamide, IAP-VHL hetero-PROTAC 9

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C61H82N8O9S
Molecular Weight:
1103.42
UNSPSC Code:
12352200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

BIR domain-targeting degrader of inhibitor of apoptosis proteins (IAPs) cIAP1/2 and XIAP.



CST626 is a degrader of cellular inhibitor of apoptosis (IAP) proteins (cIAP1/cIAP2/XIAP DC50 post 16h = 2.4/6.2/0.7 nM with >99% degradation observed post 3h treatment at 100 nM; MM1S cells) that effectively reduces the viability of hematological cancer cultures, including MM (IC50 post 96h = 8.5 nM/NCI-H929, 1.14µM/JJN3, 2.54 µM/RPMI-8826), AML (IC50 post 96h = 2.1 nM/MOLM13, 420 nM/K562, 1.17 µM/HEL) and DLBCL (IC50 post 96h = 1.6 nM/SUDHL6, 460 nM/DB, 1.69 µM/SUDHL4). CST626 is composed of a von Hippel-Lindau (VHL) ligand VH032 derivative linked to a monovalent Smac (DIABLO) AVPI motif-based IAP BIR domain-targeting ligand.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yuen Lam Dora Ng et al.
Journal of medicinal chemistry, 66(7), 4703-4733 (2023-03-31)
Proteolysis targeting chimeras (PROTACs) represent a new pharmacological modality to inactivate disease-causing proteins. PROTACs operate via recruiting E3 ubiquitin ligases, which enable the transfer of ubiquitin tags onto their target proteins, leading to proteasomal degradation. However, several E3 ligases are

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service